NMTR - Tiny 9 Meters Bio moving after William Blair coverage spots big opportunity

William Blair initiates coverage on $95M market cap 9 Meters Biotech (NMTR), saying its pipeline is a "blockbuster in the making."The current Phase 3 study of larazotide should show results in Q4 of 2021, says Blair, and, if positive, the company will file for conditional approval in the U.S. Even failure to receive conditional approval shouldn't be too much of a near-term risk for the stock. The key will be the positive Phase 3 result.Blair says comparable companies trade at a market cap of $1.9B vs. 9 Meters' $95M.Shares are up 10% premarket.More on larazotide here: 9 Meters Bio nabs new patent for larazotide in U.S. (July 28)

For further details see:

Tiny 9 Meters Bio moving after William Blair coverage spots big opportunity